Relay Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. (RLAY) on March 11, 2026, covering an event that occurred on March 6, 2026. The filing addresses corporate governance changes rather than operational or financial performance updates.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or performance metrics.
Material Changes
On March 6, 2026, the Board of Directors approved an amendment and restatement of the Company's bylaws. The primary change designates the federal district courts of the United States as the exclusive forum for resolving complaints arising under the Securities Act of 1933, the Securities Exchange Act of 1934, or related rules, unless the Company consents in writing to an alternative forum.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The exclusive forum provision is a standard governance mechanism intended to centralize litigation related to federal securities laws, though it may limit shareholder ability to pursue claims in state courts or other jurisdictions.
Key Facts for Investor Verification
- The exclusive forum provision applies specifically to claims under federal securities laws.
- The amendment became effective immediately upon Board approval on March 6, 2026.
- The full text of the Second Amended and Restated Bylaws is available as Exhibit 3.1 to this filing.
- No financial data or operational updates are included in this specific report.